miR-145 has been hypothesised as a potential gastric cancer suppressor and indeed Sui demonstrated that transfection with an miR-145 inhibitor reversed the anti-neoplastic effects of lidocaine on the cancer cells and the NF-κB and MEK/ERK pathways (63). Here, MAP2K7 is linked to gastric cancer.